<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: currently derives", fill: "#f93"},
{source: "2: currently derives", target: "2: revenues from", fill: "#f93"},
{source: "2: revenues from", target: "2: Humana Agreements ", fill: "#f93"},
{source: "2: Humana Agreements ", target: "2: which provide", fill: "#f93"},
{source: "2: which provide", target: "2: capitated fees", fill: "#f93"},
{source: "2: currently derives", target: "8: would adversely affect", fill: "#1034a6"},
{source: "8: would adversely affect", target: "8: operations", fill: "#1034a6"},
{source: "8: would adversely affect", target: "19: medical expenses", fill: "#f00"},
{source: "19: medical expenses", target: "19: higher than", fill: "#f00"},
{source: "19: higher than", target: "19: utilization", fill: "#f00"},
{source: "19: utilization", target: "19: existing healthcare", fill: "#f00"},
{source: "19: existing healthcare", target: "19: technologies", fill: "#f00"},
{source: "19: technologies", target: "19: healthcare services", fill: "#f00"},
{source: "19: healthcare services", target: "19: pharmaceuticals whether as", fill: "#f00"},
{source: "19: pharmaceuticals whether as", target: "19: mandated benefits", fill: "#f00"},
{source: "19: mandated benefits", target: "19: healthcare laws", fill: "#f00"},
{source: "19: healthcare laws", target: "19: regulations", fill: "#f00"},
{source: "19: regulations", target: "19: periodic renegotiation", fill: "#f00"},
{source: "19: periodic renegotiation", target: "19: provider contracts with", fill: "#f00"},
{source: "19: provider contracts with", target: "19: specialist physicians hospitals", fill: "#f00"},
{source: "19: specialist physicians hospitals", target: "19: ancillary providers", fill: "#f00"},
{source: "19: ancillary providers", target: "19: demographics", fill: "#f00"},
{source: "19: demographics", target: "19: medical trends", fill: "#f00"},
{source: "19: medical trends", target: "19: affecting them", fill: "#f00"},
{source: "19: affecting them", target: "19: contractual", fill: "#f00"},
{source: "19: contractual", target: "19: disputes with providers hospitals", fill: "#f00"},
{source: "19: disputes with providers hospitals", target: "19: service providers within", fill: "#f00"},
{source: "19: service providers within", target: "19: catastrophes major epidemics", fill: "#f00"},
{source: "19: medical expenses", target: "20: Metropolitan ", fill: "#fdfd96"},
{source: "20: Metropolitan ", target: "20: costs through", fill: "#fdfd96"},
{source: "20: costs through", target: "20: techniques", fill: "#fdfd96"},
{source: "20: techniques", target: "20: capitation", fill: "#fdfd96"},
{source: "20: capitation", target: "20: relationships with primary care physicians", fill: "#fdfd96"},
{source: "20: relationships with primary care physicians", target: "20: providers advance approval", fill: "#fdfd96"},
{source: "20: providers advance approval", target: "20: hospital services", fill: "#fdfd96"},
{source: "20: hospital services", target: "20: referral requirements case", fill: "#fdfd96"},
{source: "20: referral requirements case", target: "20: disease management", fill: "#fdfd96"},
{source: "20: disease management", target: "20: quality assurance programs", fill: "#fdfd96"},
{source: "20: Metropolitan ", target: "38: The Company ", fill: "#93ccea"},
{source: "38: The Company ", target: "38: cannot predict whether", fill: "#93ccea"},
{source: "38: cannot predict whether", target: "38: Congress ", fill: "#93ccea"},
{source: "38: Congress ", target: "38: requested by", fill: "#93ccea"},
{source: "38: requested by", target: "38: President ", fill: "#93ccea"},
{source: "38: The Company ", target: "139: regulations", fill: "#fff8e7"},
{source: "139: regulations", target: "139: interpretations", fill: "#fff8e7"},
{source: "139: interpretations", target: "139: enactment", fill: "#fff8e7"},
{source: "139: enactment", target: "139: new regulations could adversely affect", fill: "#fff8e7"},
{source: "139: new regulations could adversely affect", target: "139: imposing additional license registration", fill: "#fff8e7"},
{source: "139: imposing additional license registration", target: "139: additional", fill: "#fff8e7"},
{source: "139: additional", target: "139: capital reserve", fill: "#fff8e7"},
{source: "139: capital reserve", target: "139: requirements", fill: "#fff8e7"},
{source: "139: requirements", target: "139: administrative", fill: "#fff8e7"},
{source: "139: administrative", target: "139: corporate restructuring", fill: "#fff8e7"},
{source: "139: corporate restructuring", target: "139: intercompany transactions with", fill: "#fff8e7"},
{source: "139: intercompany transactions with", target: "139: affiliates", fill: "#fff8e7"},
{source: "139: affiliates", target: "139: subsidiaries", fill: "#fff8e7"},
{source: "139: subsidiaries", target: "139: restructure", fill: "#fff8e7"},
{source: "139: restructure", target: "139: relationships with providers", fill: "#fff8e7"},
{source: "139: relationships with providers", target: "139: different programs", fill: "#fff8e7"},
{source: "139: regulations", target: "START_HERE", fill: "#fff8e7"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Metropolitan_(train)">Metropolitan (train)</a></td>
      <td>The Metropolitan (official spelling: MetropolitaN) was a premium passenger train service between the cities of Cologne and Hamburg in Germany. Meant as an alternative to air transport, the first-class-only trains were operated from 1 August 1999 until 11 December 2004 by Metropolitan Express Train GmbH (MET) based in Bad Homburg, a wholly owned subsidiary of the DB Fernverkehr AG wholly owned subsidiary of Deutsche Bahn AG. Service was discontinued in December 2004 due to low usage and profitability; the custom made coaches are since then deployed in Intercity traffic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Metropolitan_borough">Metropolitan borough</a></td>
      <td>A metropolitan borough is a type of local government district in England, and is a subdivision of a metropolitan county. Created in 1974 by the Local Government Act 1972, metropolitan boroughs are defined in English law as metropolitan districts.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Metropolitan_statistical_area">Metropolitan statistical area</a></td>
      <td>In the United States, a metropolitan statistical area (MSA) is a geographical region with a relatively high population density at its core and close economic ties throughout the area. Such regions are neither legally incorporated as a city or town would be, nor are they legal administrative divisions like counties or separate entities such as states; because of this, the precise definition of any given metropolitan area can vary with the source.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Metropolitan_and_non-metropolitan_counties_of_England">Metropolitan and non-metropolitan counties of England</a></td>
      <td>Metropolitan and non-metropolitan counties are one of the four levels of subdivisions of England used for the purposes of local government outside Greater London and the Isles of Scilly. As originally constituted, the metropolitan and non-metropolitan counties each consisted of multiple districts, had a county council and were also the counties for the purposes of Lieutenancies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Metropolitan_Police">Metropolitan Police</a></td>
      <td>The Metropolitan Police Service (MPS), formerly and still commonly known as the Metropolitan Police (and informally as the Met Police, the Met, Scotland Yard, or the Yard), is the territorial police force responsible for the prevention of crime and law enforcement in Greater London. In addition, the Met Police is also responsible for some specialised matters throughout the United Kingdom; these responsibilities include co-ordinating and leading national counter-terrorism measures and the personal safety of specific individuals, such as the Monarch and other members of the Royal Family, members of the Government, and other officials (such as the Leader of the Opposition).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Metropolitan_Museum_of_Art">Metropolitan Museum of Art</a></td>
      <td>The Metropolitan Museum of Art of New York City, colloquially "the Met", is the largest art museum in the Western Hemisphere. Its permanent collection contains over two million works, divided among 17 curatorial departments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Metropolitan_bishop">Metropolitan bishop</a></td>
      <td>In Christian churches with episcopal polity, the rank of metropolitan bishop, or simply metropolitan (alternative obsolete form: metropolite), pertains to the diocesan bishop or archbishop of a metropolis.\nOriginally, the term referred to the bishop of the chief city of a historical Roman province, whose authority in relation to the other bishops of the province was recognized by the First Council of Nicaea (AD 325).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_elicitation">Requirements elicitation</a></td>
      <td>In requirements engineering, requirements elicitation is the practice of researching and discovering the requirements of a system from users, customers, and other stakeholders. The practice is also sometimes referred to as "requirement gathering".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_analysis">Requirements analysis</a></td>
      <td>In systems engineering and software engineering, requirements analysis focuses on the tasks that determine the needs or conditions to meet the new or altered product or project, taking account of the possibly conflicting requirements of the various stakeholders, analyzing, documenting, validating and managing software or system requirements.Requirements analysis is critical to the success or failure of a systems or software project. The requirements should be documented, actionable, measurable, testable, traceable, related to identified business needs or opportunities, and defined to a level of detail sufficient for system design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirement">Requirement</a></td>
      <td>In product development and process optimization, a requirement is a singular documented physical or functional need that a particular design, product or process aims to satisfy. It is commonly used in a formal sense in engineering design, including for example in systems engineering, software engineering, or enterprise engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Company">Company</a></td>
      <td>A company, abbreviated as co., is a legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective. Company members share a common purpose and unite to achieve specific, declared goals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holding_company">Holding company</a></td>
      <td>A holding company is a company whose primary business is holding a controlling interest in the securities of other companies. A holding company usually does not produce goods or services itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/East_India_Company">East India Company</a></td>
      <td>The East India Company (EIC) was an English, and later British, joint-stock company founded in 1600. It was formed to trade in the Indian Ocean region, initially with the East Indies (the Indian subcontinent and Southeast Asia), and later with East Asia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Honest_Company">The Honest Company</a></td>
      <td>The Honest Company, Inc. is an American consumer goods company, founded by actress Jessica Alba.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-functional_requirement">Non-functional requirement</a></td>
      <td>In systems engineering and requirements engineering, a non-functional requirement (NFR) is a requirement that specifies criteria that can be used to judge the operation of a system, rather than specific behaviours. They are contrasted with functional requirements that define specific behavior or functions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_engineering">Requirements engineering</a></td>
      <td>Requirements engineering (RE) is the process of defining, documenting, and maintaining requirements in the engineering design process. It is a common role in systems engineering and software engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Age_of_candidacy">Age of candidacy</a></td>
      <td>Age of candidacy is the minimum age at which a person can legally hold certain elected government offices. In many cases, it also determines the age at which a person may be eligible to stand for an election or be granted ballot access.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_requirements_document">Market requirements document</a></td>
      <td>A market requirements document (MRD) in project management and systems engineering, is a document that expresses the customer's wants and needs for the product or service.\nIt is typically written as a part of product marketing or product management.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_British_citizens">Visa requirements for British citizens</a></td>
      <td>Visa requirements for British citizens are administrative entry restrictions by the authorities of other states placed on citizens of the United Kingdom. As of 30 April 2022, British citizens had visa-free or visa on arrival access to 187 countries and territories, ranking their passport 5th in terms of travel freedom (tied with France, Ireland and Portugal) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Functional_requirement">Functional requirement</a></td>
      <td>In software engineering and systems engineering, a functional requirement defines a function of a system or its component, where a function is described as a specification of behavior between inputs and outputs.Functional requirements may involve calculations, technical details, data manipulation and processing, and other specific functionality that define what a system is supposed to accomplish. Behavioral requirements describe all the cases where the system uses the functional requirements, these are captured in use cases.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>METROPOLITAN HEALTH NETWORKS INC    ITEM 1A  RISK FACTORS    The PSNapstas Operations are <font color="blue">Dependent </font>on Humana, Inc</td>
    </tr>
    <tr>
      <td>The PSN <font color="blue">currently derives</font>, and expect to continue to derive, the vast majority  of its <font color="blue">revenues from</font> its <font color="blue"><font color="blue">Humana Agreements</font> </font><font color="blue">which provide</font> for the receipt of  <font color="blue"><font color="blue">capitated fee</font>s</font></td>
    </tr>
    <tr>
      <td>For the twelve months ended <font color="blue">December </font>31, 2005, approximately 98prca  of its revenue was obtained from these <font color="blue">Humana Agreements</font></td>
    </tr>
    <tr>
      <td>Humana <font color="blue">may immediately</font>  <font color="blue">terminate either</font> of the <font color="blue"><font color="blue">Humana Agreements</font> </font>and/or any individual physician  <font color="blue">credentialed under</font> the <font color="blue"><font color="blue">Humana Agreements</font> </font>upon the occurrence of <font color="blue">certain events</font></td>
    </tr>
    <tr>
      <td>Humana <font color="blue">may also amend</font> the material terms of the <font color="blue"><font color="blue">Humana Agreements</font> </font><font color="blue">under certain</font>  <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>BUSINESS - <font color="blue"><font color="blue">Humana Agreements</font> </font>&amp;quote  for a detailed  discussion of the <font color="blue">Humana Agreements</font></td>
    </tr>
    <tr>
      <td>Failure to maintain the <font color="blue"><font color="blue">Humana Agreements</font> </font>on favorable terms, for any reason,  <font color="blue">would <font color="blue">adversely affect</font></font> the Companyapstas results of <font color="blue">operations</font> and financial  condition</td>
    </tr>
    <tr>
      <td>A material decline in enrollees in Humanaapstas <font color="blue">Medicare Advantage </font> <font color="blue">program could also</font> have a material adverse effect on the Companyapstas results of  operation</td>
    </tr>
    <tr>
      <td>Because Most of the Companyapstas Revenue Is Established by Contract and Cannot Be  Modified During the Contract Terms, the Companyapstas Operating Margins Could be  <font color="blue">Negatively Impacted </font>if It is <font color="blue">Unable to Manage Its Medical Expenses Effectively</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">Humana Agreements</font> </font>and the <font color="blue">CMS Agreement </font>are <font color="blue">risk <font color="blue">agreements</font> under which</font> it  receives <font color="blue">monthly payments per participating</font> member ( &amp;quote <font color="blue">Participating Member </font>&amp;quote ) at a  <font color="blue">rate established by</font> the <font color="blue">agreements</font>, also called a <font color="blue">capitated fee</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">accordance</font>  with the <font color="blue">agreements</font>, the <font color="blue">total monthly payment</font> is a function of the number of  <font color="blue">Participating Members</font>, <font color="blue">regardless</font> of the <font color="blue">actual <font color="blue">utilization</font> rate</font> of covered  services</td>
    </tr>
    <tr>
      <td>In return, the PSN or MHP, as applicable, through its <font color="blue">affiliated</font>  providers, assumes full <font color="blue">financial responsibility</font> for the provision of all  <font color="blue"><font color="blue">necessary</font> medical care</font> to the <font color="blue">Participating Members</font>, <font color="blue">regardless</font> of whether or  not its <font color="blue">affiliated</font> providers directly provide the <font color="blue">covered <font color="blue">medical services</font></font></td>
    </tr>
    <tr>
      <td>- 19 -  <PAGE>    To the extent that the <font color="blue"><font color="blue">Participating Members</font> </font>require more care than is  anticipated, <font color="blue">aggregate <font color="blue">capitation</font> rates may</font> be insufficient to cover the costs  <font color="blue">associated with</font> the treatment of such <font color="blue">Participating Members</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">medical expense</font>s</font>  exceed the Companyapstas estimates, except in very limited <font color="blue">circumstances</font>, it will be  unable to increase the premiums it receives under these <font color="blue">contracts during</font> the  then-current terms</td>
    </tr>
    <tr>
      <td><font color="blue">Relatively </font>small changes in the Companyapstas ratio of <font color="blue">medical expense</font> to revenue  can create <font color="blue">significant</font> changes in its financial results</td>
    </tr>
    <tr>
      <td>Accordingly, the  failure to <font color="blue">adequately</font> predict and control <font color="blue"><font color="blue">medical expense</font>s</font> and to make  reasonable estimates and maintain <font color="blue">adequate accruals</font> for <font color="blue">incurred but</font> not  reported, or IBNR, claims, may have a material adverse effect on the Companyapstas  <font color="blue">financial condition</font>, results of <font color="blue">operations</font>, or <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>Historically, the Companyapstas <font color="blue"><font color="blue">medical expense</font>s</font> as a percentage of revenue have  fluctuated</td>
    </tr>
    <tr>
      <td>Factors that may cause <font color="blue"><font color="blue">medical expense</font>s</font> to exceed estimates include:          o     <font color="blue">higher than</font> expected <font color="blue">utilization</font> of new or <font color="blue">existing healthcare</font>              services or <font color="blue">technologies</font>;          o     an increase in the cost of <font color="blue">healthcare services</font> and supplies,              including pharmaceuticals, whether as a result of inflation or              otherwise;          o     changes to <font color="blue">mandated benefits</font> or other changes in <font color="blue">healthcare laws</font>,              <font color="blue">regulations</font>, and practices;          o     Humanaapstas <font color="blue">periodic renegotiation</font> of <font color="blue">provider contracts with</font>              specialist physicians, hospitals and <font color="blue">ancillary providers</font>;          o     <font color="blue">periodic renegotiation</font> of IP contracts;          o     changes in the <font color="blue">demographics</font> of our members and <font color="blue">medical trends</font>              <font color="blue">affecting them</font>;          o     <font color="blue">contractual</font> or claims disputes with providers, hospitals, or other              <font color="blue"><font color="blue">service providers</font> within</font> the Humana network; and          o     the occurrence of catastrophes, major epidemics, or acts of              terrorism</td>
    </tr>
    <tr>
      <td><font color="blue">Metropolitan </font>attempts to control these <font color="blue">costs through</font> a variety of <font color="blue">techniques</font>,  including <font color="blue">capitation</font> and other risk-sharing payment methods, collaborative  <font color="blue"><font color="blue">relationships with</font> <font color="blue">primary care</font> physicians</font> and other providers, advance approval  for <font color="blue">hospital services</font> and referral <font color="blue">requirements</font>, case and <font color="blue">disease <font color="blue">management</font></font> and  <font color="blue">quality assurance programs</font>, information systems, and reinsurance</td>
    </tr>
    <tr>
      <td>Despite its  efforts and programs to manage its <font color="blue"><font color="blue">medical expense</font>s</font>, <font color="blue">Metropolitan </font>may not be  able to continue to manage these <font color="blue">expenses <font color="blue">effectively</font></font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Effective July </font>1, 2005, MHP <font color="blue">entered into</font> the <font color="blue">CMS Agreement </font>to begin offering  <font color="blue">Medicare Advantage </font>plans to Medicare <font color="blue">beneficiaries</font> in six Florida <font color="blue">counties which</font>  include the cities of Fort Pierce, Port St</td>
    </tr>
    <tr>
      <td>The <font color="blue">initial term</font> of the <font color="blue">CMS Agreement </font><font color="blue">expired on</font> <font color="blue">December </font>31, 2005  and was subject to <font color="blue">annual renewal at</font> the election of CMS A new <font color="blue">CMS Agreement </font> was <font color="blue">entered into</font> effective January 1, 2006 and <font color="blue">expires on</font> <font color="blue">December </font>31, 2006</td>
    </tr>
    <tr>
      <td>Pursuant to the CMS Agreements, MHP is required to <font color="blue"><font color="blue">comply with</font> federal</font> <font color="blue">Medicare  </font>laws and <font color="blue">regulations</font> and the <font color="blue">CMS Agreement </font>is subject to <font color="blue"><font color="blue">termination</font> by</font> CMS in  the event of MHPapstas <font color="blue">noncompliance</font></td>
    </tr>
    <tr>
      <td>If MHP is unable to renew or to <font color="blue">successfully</font>  rebid for the CMS Agreement, or if the <font color="blue">CMS Agreement </font>is terminated, its business  would be <font color="blue">negatively impacted</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, <font color="blue">substantially</font> all of the Companyapstas revenues were  <font color="blue">indirectly</font> or <font color="blue">directly derived from <font color="blue">reimbursement</font>s generated by</font> <font color="blue">Medicare  </font>Advantage health plans</td>
    </tr>
    <tr>
      <td>As a result, its revenue and <font color="blue">profitability</font> are <font color="blue">dependent</font>  on <font color="blue">government</font> funding levels <font color="blue">for <font color="blue">Medicare Advantage </font></font>programs</td>
    </tr>
    <tr>
      <td>The <font color="blue">Medicare  </font>programs are subject to statutory and <font color="blue">regulatory</font> changes, <font color="blue">retroactive</font> and  prospective rate <font color="blue">adjustment</font>s, <font color="blue">administrative</font> rulings and <font color="blue">funding restrictions</font>,  any of <font color="blue">which could</font> have the effect of limiting or <font color="blue">reducing <font color="blue">reimbursement</font> levels</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">government</font> programs, as well as private insurers such as Humana, have  taken and <font color="blue">may continue</font> to take steps to control the cost, use and delivery of  <font color="blue">health care services</font></td>
    </tr>
    <tr>
      <td>Any changes that limit or reduce Medicare <font color="blue">reimbursement</font>  <font color="blue">levels could</font> have a material adverse effect on the Companyapstas business</td>
    </tr>
    <tr>
      <td>For  example, the <font color="blue">following events could</font> result in an adverse effect on its results  of <font color="blue">operations</font>:          o     <font color="blue">reductions</font> in or <font color="blue">limitations</font> of <font color="blue">reimbursement</font> amounts or <font color="blue">rates under</font>              programs;          o     <font color="blue">reductions</font> in funding of programs;          o     <font color="blue">elimination</font> of coverage for <font color="blue">certain benefits</font>; or          o     <font color="blue">elimination</font> of coverage for <font color="blue">certain <font color="blue">individuals</font></font> or <font color="blue">treatments under</font>              programs</td>
    </tr>
    <tr>
      <td>For instance, the <font color="blue">President </font><font color="blue">recently signed</font> the <font color="blue">Deficit Reduction Act </font>of 2005</td>
    </tr>
    <tr>
      <td>According to the Congressional Budget Office, the provisions of this Act are  expected to <font color="blue">reduce federal</font> Medicare spending by dlra6dtta4 billion over the next five  years</td>
    </tr>
    <tr>
      <td>In addition, in his 2007 budget proposal, <font color="blue">President </font>Bush has requested that  <font color="blue">Congress </font>implement <font color="blue">legislative</font> changes to produce approximately dlra35dtta9 billion in  Medicare <font color="blue">savings over five years</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue"><font color="blue">cannot predict</font> whether</font> <font color="blue">Congress </font> will implement the changes <font color="blue">requested by</font> the <font color="blue">President </font>and, if implemented, the  sources of such savings</td>
    </tr>
    <tr>
      <td>The MMA <font color="blue">substantially</font> changed the Medicare program and is complex and  wide-ranging</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has not <font color="blue">yet been able</font> to <font color="blue">fully assess</font> the impact of  all of the changes</td>
    </tr>
    <tr>
      <td>While it anticipates that many of these changes will  <font color="blue">generally benefit</font> the <font color="blue">Medicare Advantage </font>sector, <font color="blue">certain provisions</font> of the MMA  <font color="blue">may increase competition</font>, create <font color="blue">challenges <font color="blue">with respect</font></font> to educating the PSNapstas  and MHPapstas existing and potential <font color="blue"><font color="blue">Participating Members</font> </font>about the changes, and  create other risks and substantial and <font color="blue">potentially adverse uncertainties</font>,  including the following:          o     <font color="blue">Increased </font><font color="blue">reimbursement</font> rates <font color="blue">for <font color="blue">Medicare Advantage </font></font>plans could              result in an increase in the number of plans that <font color="blue">participate</font> in the              Medicare program</td>
    </tr>
    <tr>
      <td>This could create <font color="blue">new competition</font> that could              <font color="blue">adversely affect</font> the number of <font color="blue"><font color="blue">Participating Members</font> </font>the <font color="blue">PSN or MHP </font>             serve and their respective results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>- 21 -  <PAGE>          o     Managed care companies began offering various new products beginning              in 2006 pursuant to the MMA, including <font color="blue">regional preferred provider</font>              <font color="blue"><font color="blue">organization</font>s</font>, or PPOs, and private fee-for-service plans</td>
    </tr>
    <tr>
      <td><font color="blue">Medicare  </font>            PPOs and private fee-for-service plans allow their members more              <font color="blue">flexibility</font> in selecting physicians than <font color="blue">Medicare Advantage </font>HMOs,              <font color="blue">which typically</font> require members to <font color="blue">coordinate with</font> a <font color="blue">primary care</font>              physician</td>
    </tr>
    <tr>
      <td>The MMA has encouraged the creation of regional <font color="blue">PPOs              </font><font color="blue">through various incentives</font>, including <font color="blue">certain risk corridors</font>, or              cost-<font color="blue">reimbursement</font> provisions, a <font color="blue">stabilization fund</font> for incentive              payments, and <font color="blue">special payments</font> to hospitals not <font color="blue">otherwise contracted</font>              with a <font color="blue">Medicare Advantage </font>plan who <font color="blue">treat regional</font> plan enrollees</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>currently is unable to determine whether the formation              of regional Medicare PPOs and private fee-for-service plans will              affect its PSNapstas or HMOapstas <font color="blue">relative attractiveness</font> to existing and              potential Medicare members in its <font color="blue">service areas</font></td>
    </tr>
    <tr>
      <td>o     <font color="blue">Beginning </font>in 2006, the payments for the local and regional <font color="blue">Medicare  </font>            Advantage plans will be <font color="blue">based on</font> a <font color="blue">competitive bidding process</font> that              <font color="blue">may directly</font> or <font color="blue">indirectly</font> cause the PSN and/or MHP to decrease the              amount of premiums paid to it or cause it to increase the benefits              it offers</td>
    </tr>
    <tr>
      <td>o     <font color="blue">Beginning </font>in 2006, Medicare <font color="blue">beneficiaries</font> generally have a more              limited <font color="blue">annual <font color="blue">enrollment</font> period during which</font> they can choose to              <font color="blue">participate</font> in a <font color="blue">Medicare Advantage </font>plan or receive <font color="blue">benefits under</font>              the traditional fee-for-service Medicare program</td>
    </tr>
    <tr>
      <td>After the annual              <font color="blue">enrollment</font> period, most Medicare <font color="blue">beneficiaries</font> will not be permitted              to change their Medicare benefits</td>
    </tr>
    <tr>
      <td>This  &amp;quote lock-in &amp;quote  may make it              <font color="blue">difficult</font> for MHP to retain an adequate sales force</td>
    </tr>
    <tr>
      <td>The new annual              <font color="blue">enrollment</font> process and subsequent  &amp;quote lock-in &amp;quote  provisions of the <font color="blue">MMA              </font>may <font color="blue">adversely affect</font> the Companyapstas level of <font color="blue">revenue growth as</font> it              will limit its ability to market to and <font color="blue">enroll new</font> Participating              Members in its established <font color="blue">service areas</font> outside of the annual              <font color="blue">enrollment</font> period</td>
    </tr>
    <tr>
      <td>Such <font color="blue">limitations</font> could adversely and <font color="blue">materially</font>              affect its <font color="blue">profitability</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>o     <font color="blue">Beginning </font>in 2006, <font color="blue">managed care</font> companies that offer <font color="blue">Medicare  </font>            Advantage plans are required to <font color="blue">offer prescription <font color="blue">drug benefits</font> as</font>              part of their <font color="blue">Medicare Advantage </font>plans</td>
    </tr>
    <tr>
      <td>Managed care plans offering              <font color="blue">drug benefits</font> are, under the new law, called MA-PDs</td>
    </tr>
    <tr>
      <td>It is not known              at this time whether the <font color="blue">government</font>al payments will be adequate to              cover the <font color="blue">actual costs</font> for these new MA-PD benefits or whether it              will be able to profitably or <font color="blue">competitively manage</font> its MA-PD              Individuals who are enrolled in a <font color="blue">Medicare Advantage </font>plan must              receive their <font color="blue">drug coverage through</font> their <font color="blue">Medicare Advantage </font>             <font color="blue">prescription drug</font> plan</td>
    </tr>
    <tr>
      <td><font color="blue">Enrollees </font>may prefer a stand-alone drug plan              and may cease to be a <font color="blue">Participating Member </font>in order to <font color="blue">participate</font>              in a stand-alone drug plan</td>
    </tr>
    <tr>
      <td>Accordingly, the new <font color="blue">Medicare Part D              </font><font color="blue">prescription drug</font> benefit could reduce the PSNapstas and/or MHPapstas              <font color="blue">Participating Member </font><font color="blue">enrollment</font> and revenues</td>
    </tr>
    <tr>
      <td>CMS has implemented a <font color="blue">risk <font color="blue">adjustment</font> payment system</font> for Medicare health plans  to improve the accuracy of payments and <font color="blue">establish incentives</font> for Medicare plans  to enroll and <font color="blue">treat less healthy</font> Medicare <font color="blue">beneficiaries</font></td>
    </tr>
    <tr>
      <td>CMS is phasing-in this  <font color="blue">payment methodology with</font> a <font color="blue">risk <font color="blue">adjustment</font> model</font> that bases a portion of the  total CMS <font color="blue">reimbursement</font> payments on various clinical and <font color="blue">demographic factors</font>  including hospital inpatient diagnoses, diagnostic data from ambulatory  <font color="blue">treatment settings</font>, including <font color="blue">hospital outpatient <font color="blue">facilities</font></font> and physician  visits, gender, age, and Medicaid <font color="blue">eligibility</font></td>
    </tr>
    <tr>
      <td>CMS requires that all managed  care companies capture, collect, and submit the <font color="blue"><font color="blue">necessary</font> diagnosis code</font>  information to CMS twice a year for <font color="blue">reconciliation with</font> CMSapstas <font color="blue">internal database</font></td>
    </tr>
    <tr>
      <td>As part of the phase-in, during 2003, risk <font color="blue">adjusted payments</font> accounted for 10prca  of Medicare health plan payments, with the remaining 90prca being reimbursed in  <font color="blue">accordance</font> with the traditional CMS <font color="blue">demographic rate books</font></td>
    </tr>
    <tr>
      <td>The portion of risk  <font color="blue">adjusted payments</font> was increased to 30prca in 2004, 50prca in 2005, and 75prca in 2006,  and <font color="blue">will increase</font> to 100prca in 2007</td>
    </tr>
    <tr>
      <td>As a result of this process, it is <font color="blue">difficult</font>  to predict with <font color="blue">certainty</font> the Companyapstas <font color="blue">future revenue</font> or <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In  addition, MHPapstas and/or Humanaapstas <font color="blue">risk scores</font> for any <font color="blue">period may</font> result in  favorable or <font color="blue">unfavorable <font color="blue">adjustment</font>s</font> to the <font color="blue">payments directly</font> or <font color="blue">indirectly</font>  received from CMS and the Companyapstas Medicare <font color="blue">premium revenue</font></td>
    </tr>
    <tr>
      <td>There can be no  assurance that the Companyapstas <font color="blue">contracting physicians</font> and <font color="blue">hospitals will</font> be  successful in improving the accuracy of related <font color="blue">recording diagnostic code</font>  information and <font color="blue">thereby enhancing</font> its <font color="blue">risk scores</font></td>
    </tr>
    <tr>
      <td>- 22 -  <PAGE>    Since 2003, payments to <font color="blue">Medicare Advantage </font>plans have <font color="blue">also been <font color="blue">adjusted by</font></font> a   &amp;quote budget <font color="blue">neutrality</font> &amp;quote  factor that was <font color="blue">implemented by</font> <font color="blue">Congress </font>and CMS to prevent  health plan payments from being reduced overall while, at the same time,  directing higher, risk <font color="blue">adjusted payments</font> to plans with more <font color="blue">chronically</font> ill  enrollees</td>
    </tr>
    <tr>
      <td>In general, this <font color="blue">adjustment</font> has <font color="blue">favorably impacted payments</font> to all  <font color="blue">Medicare Advantage </font>plans</td>
    </tr>
    <tr>
      <td>The Presidentapstas budget for 2005 assumed the phasing  out of the budget <font color="blue">neutrality</font> <font color="blue">adjustment</font>s over a five year period from 2007  through 2011</td>
    </tr>
    <tr>
      <td>The <font color="blue">President </font><font color="blue">recently signed</font> the <font color="blue">Deficit Reduction Act </font>of 2005  which, among other changes, provides for an accelerated phase-out of budget  <font color="blue">neutrality</font> for risk <font color="blue">adjustment</font> of payments made to <font color="blue">Medicare Advantage </font>plans</td>
    </tr>
    <tr>
      <td>This <font color="blue">legislation will</font> have the effect of <font color="blue">reducing payments</font> to <font color="blue">Medicare Advantage </font> plans in general</td>
    </tr>
    <tr>
      <td>Consequently, <font color="blue">the Company </font>expects the premiums it receives  could be reduced, <font color="blue">dependent</font> upon MHPapstas and Humanaapstas <font color="blue">risk scores</font></td>
    </tr>
    <tr>
      <td>A Disruption in Its or Humanaapstas Healthcare Provider Networks Could Have an  <font color="blue">Adverse Effect </font>on The Companyapstas Operations and Profitability</td>
    </tr>
    <tr>
      <td>The PSNapstas <font color="blue">operations</font> are <font color="blue">dependent</font> on the <font color="blue">management</font> information systems of  Humana</td>
    </tr>
    <tr>
      <td>Humana provides the PSN with claims processing, billing services, data  <font color="blue">collection</font> and other information, including reports and <font color="blue">calculations</font> of costs of  <font color="blue">services provided</font> and payments to be received by the <font color="blue">PSN While the PSN </font>relies  on Humanaapstas information systems, it does not own or <font color="blue">control such systems</font> and,  <font color="blue">accordingly</font>, has limited ability to ensure that these systems are properly  maintained, serviced and updated</td>
    </tr>
    <tr>
      <td>In addition, information <font color="blue">systems such as</font> these  may be vulnerable to failure, acts of sabotage and obsolescence</td>
    </tr>
    <tr>
      <td>Although the  PSN has the <font color="blue">contractual</font> right to receive various information and data from  Humana, and it receives monthly downloads of claims data from Humana, the PSNapstas  business and results of <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue">adversely affect</font>ed by  its <font color="blue">inability</font>, for any reason, to timely receive information from Humana</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of the PSNapstas <font color="blue">Total Medical Expenses </font>are payable to  entities that are not members and/or directly contracted with the PSN Although  virtually all of <font color="blue">such entities</font> are Humana <font color="blue">approved <font color="blue">service providers</font></font>, and  although the PSN can provide Humana input <font color="blue">with respect</font> to Humanaapstas service  providers, the PSN does not control the <font color="blue">process by which</font> Humana <font color="blue">negotiates</font>  and/or contracts with <font color="blue">service providers</font> in the Humana <font color="blue">Medicare Advantage </font> network</td>
    </tr>
    <tr>
      <td>- 23 -  <PAGE>    <font color="blue">The Company </font>Depends on <font color="blue">Third Parties to Provide It </font>with <font color="blue">Crucial Information </font>and  Data</td>
    </tr>
    <tr>
      <td>The Companyapstas PSN <font color="blue">operations</font> are <font color="blue">dependent</font> on the <font color="blue">management</font> information systems  of Humana</td>
    </tr>
    <tr>
      <td>Humana provides it with claims processing, billing services, data  <font color="blue">collection</font> and other information, including reports and <font color="blue">calculations</font> of costs of  <font color="blue">services provided</font> and payments to be received by us</td>
    </tr>
    <tr>
      <td>While it <font color="blue">relies on</font> Humanaapstas  information systems, it does not own or <font color="blue">control such systems</font> and, <font color="blue">accordingly</font>,  has limited ability to ensure that it is properly maintained, serviced and  updated</td>
    </tr>
    <tr>
      <td>In addition, information <font color="blue">systems such as</font> these may be vulnerable to  failure, acts of sabotage and obsolescence</td>
    </tr>
    <tr>
      <td>Although it has the <font color="blue">contractual</font>  right to receive various information and data from Humana, and it receives  monthly downloads of claims data from Humana, its business and results of  <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue">adversely affect</font>ed by its <font color="blue">inability</font>, for any  reason, to timely receive information from Humana</td>
    </tr>
    <tr>
      <td>MHP <font color="blue">relies on</font> HFAS, a third party service provider, to provide various  <font color="blue">administrative</font> and <font color="blue">management</font> services, including, but not limited to, claims  processing and <font color="blue">adjudication</font>, certain <font color="blue">management</font> information services, <font color="blue">regulatory</font>  reporting and customer services pursuant to the terms of the Services Agreement</td>
    </tr>
    <tr>
      <td>The <font color="blue">initial term</font> of the <font color="blue">Services Agreement </font><font color="blue">expires on</font> June 30, 2010 and  thereafter is <font color="blue">automatically renewable</font> for <font color="blue">additional</font> one-year terms</td>
    </tr>
    <tr>
      <td>After the  <font color="blue">initial term</font>, either party may terminate the <font color="blue">Services Agreement </font>for any reason  upon 180 days written notice</td>
    </tr>
    <tr>
      <td>Either <font color="blue">party may also terminate</font> the Services  Agreement <font color="blue">upon prior written</font> notice (with a 30 day opportunity to cure) in the  event of the otherapstas material breach of the <font color="blue">Services Agreement </font>in any manner,  including but not limited to, MHPapstas failure to maintain <font color="blue">sufficient funds</font> for  HFAS to pay claims, or in the event MHP engages in or acquiesce to any act of  bankruptcy, receivership or <font color="blue">re<font color="blue">organization</font></font> or in the <font color="blue">event either party fails</font> to  secure any license, <font color="blue">government</font> approval or exemption required by law</td>
    </tr>
    <tr>
      <td>Because these matters are <font color="blue">outsourced as opposed</font> to handled <font color="blue">internally</font>, MHP has  <font color="blue">less control over</font> the manner in which these matters are handled and the data  that is <font color="blue">ultimately provided</font> to it than it would have if it handled these matters  <font color="blue">internally</font></td>
    </tr>
    <tr>
      <td>Additionally, any loss of information by HFAS could have a material  adverse effect on the Companyapstas business and the results of its <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Claims Relating to Medical Malpractice and Other Litigation Could Cause the  <font color="blue">Company to Incur Significant Expenses</font></td>
    </tr>
    <tr>
      <td>From time to time, <font color="blue">the Company </font>is party to <font color="blue">various <font color="blue">litigation</font> matters</font>, some of  <font color="blue">which seek monetary damages</font></td>
    </tr>
    <tr>
      <td>Managed care <font color="blue"><font color="blue">organization</font>s</font> may be <font color="blue">sued directly</font> for  alleged negligence, including in <font color="blue">connection with</font> the <font color="blue">credentialing</font> of network  providers or for alleged <font color="blue">improper denials</font> or delay of care</td>
    </tr>
    <tr>
      <td>In addition,  providers <font color="blue">affiliated</font> with the <font color="blue">PSN or MHP </font>involved in <font color="blue">medical care <font color="blue">decisions</font> may</font>  be exposed to the risk of <font color="blue">medical malpractice</font> claims</td>
    </tr>
    <tr>
      <td>A small percentage of  these providers do not have <font color="blue">malpractice insurance</font></td>
    </tr>
    <tr>
      <td>As a result of increased  costs or <font color="blue">inability</font> to secure <font color="blue">malpractice insurance</font>, the percentage of physicians  who do not have <font color="blue">malpractice insurance</font> may increase</td>
    </tr>
    <tr>
      <td>Although most of its network  providers are in<font color="blue">dependent</font> contractors, claimants sometimes allege that a PSN  and/or HMO should be held responsible for alleged <font color="blue">provider malpractice</font>,  <font color="blue">particularly</font> where the provider does not have <font color="blue">malpractice insurance</font>, and some  courts have permitted that theory of <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Similar to other <font color="blue">managed care</font>  companies, MHP may also be subject to other claims of <font color="blue"><font color="blue">Participating Members</font> </font>in  the ordinary course of business, including claims arising out of <font color="blue">decisions</font> to  deny or restrict <font color="blue">reimbursement</font> for services</td>
    </tr>
    <tr>
      <td>- 24 -  <PAGE>    <font color="blue">The Company </font><font color="blue">cannot predict</font> with <font color="blue">certainty</font> the <font color="blue">eventual outcome</font> of any pending  <font color="blue">litigation</font> or potential future <font color="blue">litigation</font>, and there can be <font color="blue">no assurances</font> that  it will not incur substantial expense in defending these or <font color="blue"><font color="blue">future laws</font>uits</font> or  <font color="blue">indemnifying third parties <font color="blue">with respect</font></font> to the results of such <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>The  loss of even one of these claims, if it results in a <font color="blue">significant</font> damage award,  could have a material adverse effect on its business</td>
    </tr>
    <tr>
      <td>In addition, exposure to  potential <font color="blue">liability</font> under punitive damage or other theories may <font color="blue">significant</font>ly  decrease the Companyapstas ability to settle these claims <font color="blue">on reasonable terms</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>maintains errors and <font color="blue">omissions insurance</font> and other insurance  coverage that it believes are adequate <font color="blue">based on</font> industry standards</td>
    </tr>
    <tr>
      <td>Nonetheless,  <font color="blue">potential liabilities may</font> not be <font color="blue">covered by</font> insurance, insurers may dispute  coverage or may be unable to meet their <font color="blue">obligations</font>, or the amount of insurance  coverage and/or related <font color="blue">reserves may</font> be inadequate</td>
    </tr>
    <tr>
      <td>There can be <font color="blue">no assurances</font>  that it will be able to obtain <font color="blue">insurance coverage</font> in the future, or that  <font color="blue">insurance <font color="blue">will continue</font></font> to be <font color="blue">available on</font> a cost-effective basis, if at all</td>
    </tr>
    <tr>
      <td>Moreover, even if claims <font color="blue">brought against</font> it are <font color="blue">unsuccessful</font> or <font color="blue">without merit</font>,  it would have to <font color="blue">defend itself against such</font> claims</td>
    </tr>
    <tr>
      <td>The defense of any such  <font color="blue">actions may</font> be time-consuming and costly and may distract <font color="blue">management</font>apstas  attention</td>
    </tr>
    <tr>
      <td>As a result, it may incur <font color="blue">significant</font> expenses and may be unable to  <font color="blue">effectively</font> operate its business</td>
    </tr>
    <tr>
      <td><font color="blue">Metropolitan </font>competes in the <font color="blue">highly competitive</font> and <font color="blue">regulated health care</font>  industry, which is subject to continuing changes <font color="blue">with respect</font> to the  <font color="blue">provisioning</font> of services and the selection and <font color="blue">compensation</font> of providers</td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of its <font color="blue">revenues come from</font> the <font color="blue">Humana Agreements</font></td>
    </tr>
    <tr>
      <td>Humana  <font color="blue">competes with</font> other <font color="blue">HMOs and PPOs </font>in securing and serving patients in the  <font color="blue">Medicare Advantage </font>Program</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>in other <font color="blue"><font color="blue">health care industry</font> segments</font>,  some of which have financial and other <font color="blue">resources comparable</font> to Humana, may  <font color="blue">become <font color="blue"><font color="blue">competitor</font>s</font></font> to Humana</td>
    </tr>
    <tr>
      <td>The market in Florida may become increasingly  attractive to <font color="blue">HMOs and PPOs </font>that <font color="blue">may compete with</font> <font color="blue">Humana or MHP Humana and MHP  </font>may not be able to continue to compete <font color="blue">effectively</font> in the <font color="blue">health care industry</font>  if <font color="blue"><font color="blue">additional</font> <font color="blue"><font color="blue">competitor</font>s</font> enter</font> the <font color="blue">same market</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">Humana Agreements</font> </font>are structured as one-year <font color="blue">automatically renewable</font>  <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue"><font color="blue">termination</font>s</font> for cause, Humana <font color="blue">may terminate such</font>  <font color="blue">agreements</font> upon 180 days &amp;apos  notice to the PSN of non-renewal</td>
    </tr>
    <tr>
      <td>The PSN competes  with other <font color="blue">service providers</font> for Humanaapstas business and Humana <font color="blue">competes with</font>  other <font color="blue">HMOs and PPOs </font>in securing and serving patients in the <font color="blue">Medicare Advantage </font> Program</td>
    </tr>
    <tr>
      <td>Failure to maintain favorable terms in its <font color="blue">agreements</font> with Humana would  <font color="blue">adversely affect</font> the Companyapstas results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue"><font color="blue"><font color="blue">competitor</font>s</font> vary</font> in size and scope, in terms of products and  <font color="blue">services offered</font></td>
    </tr>
    <tr>
      <td>It believes that it <font color="blue">competes directly with various national</font>,  regional and <font color="blue">local companies</font> in providing its services</td>
    </tr>
    <tr>
      <td>Some of the PSNapstas direct  <font color="blue"><font color="blue">competitor</font>s</font> are Continucare Corporation, Primary Care Associates, Inc, MCCI and  Island Doctors, all based and operating in Florida</td>
    </tr>
    <tr>
      <td><font color="blue">Metropolitan </font>believes that  Continucare Corporation, Primary Care Associates, Inc</td>
    </tr>
    <tr>
      <td>and MCCI provide PSN  services to Humana in South Florida and <font color="blue">Island Doctors </font>provides PSN services to  <font color="blue">Humana in Central Florida</font></td>
    </tr>
    <tr>
      <td>Additionally, companies in other <font color="blue">health care industry</font>  segments, some of which have financial and other resources greater than us, may  <font color="blue">become <font color="blue"><font color="blue">competitor</font>s</font></font> in providing similar <font color="blue">services at</font> any given time</td>
    </tr>
    <tr>
      <td>The market  in Florida <font color="blue">may become increasingly attractive</font> to <font color="blue">competitor</font> PSNs due to the  large population of Medicare <font color="blue">participants</font></td>
    </tr>
    <tr>
      <td><font color="blue">Humana and <font color="blue">the Company </font></font>may not be  able to continue to compete <font color="blue">effectively</font> in the <font color="blue">health care industry</font> if  <font color="blue"><font color="blue">additional</font> <font color="blue"><font color="blue">competitor</font>s</font> enter</font> the <font color="blue">same market</font>s</td>
    </tr>
    <tr>
      <td>- 25 -  <PAGE>    <font color="blue">Metropolitan </font>believes that many of its <font color="blue"><font color="blue">competitor</font>s</font> and potential <font color="blue"><font color="blue">competitor</font>s</font> are  <font color="blue">substantially</font> larger than its PSN and/or MHP and have <font color="blue">significant</font>ly greater  financial, sales and marketing, and other resources</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>believes that  most of its <font color="blue"><font color="blue">competitor</font>s</font> also have more experience operating as an HMO and that  these <font color="blue"><font color="blue">competitor</font>s</font> may be able to respond more rapidly to changes in the  <font color="blue">regulatory</font> environment in which it operates and changes in <font color="blue">managed care</font>  <font color="blue">organization</font> business or to <font color="blue">devote greater resources</font> to the <font color="blue">development</font> and  promotion of their <font color="blue">services than</font> it can</td>
    </tr>
    <tr>
      <td>Furthermore, it is the Companyapstas belief  that some of its <font color="blue"><font color="blue">competitor</font>s</font> may make <font color="blue">strategic <font color="blue"><font color="blue">acquisition</font>s</font></font> or establish  <font color="blue">cooperative relationships among themselves</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is <font color="blue">Dependent </font>upon Certain Executive Officers and Key Management  Personnel for Its Future Success</td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue">success depends</font> to a <font color="blue">significant</font> extent on the continued  <font color="blue">contributions</font> of certain of its <font color="blue">executive officers</font> and key <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>The loss of these <font color="blue">persons could</font> have a material adverse effect on the Companyapstas  business, results of <font color="blue">operations</font>, <font color="blue">financial condition</font> and plans for future  <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>While it has employment contracts with certain <font color="blue">executive officers</font>  and key members of <font color="blue">management</font>, these <font color="blue">agreements</font> may not <font color="blue">provide sufficient</font>  incentive for these persons to continue their <font color="blue">employment with</font> the Company</td>
    </tr>
    <tr>
      <td>It  <font color="blue">competes with</font> other companies in the industry for <font color="blue">executive talent</font> and there can  be no assurance that <font color="blue">highly qualified executives would</font> be readily and easily  available without delay, given the limited number of <font color="blue">individuals</font> in the industry  <font color="blue">with expertise particular</font> to its business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>These laws and <font color="blue">regulations</font>, along with the terms of its contracts and licenses,  directly or <font color="blue">indirectly</font> regulate how it does business, what services it offers,  and how it <font color="blue">interacts with</font> its members, providers, and the public</td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare  </font>laws and <font color="blue">regulations</font> are subject to frequent change and <font color="blue">varying <font color="blue"><font color="blue">interpretation</font>s</font></font></td>
    </tr>
    <tr>
      <td>Changes in existing laws or <font color="blue">regulations</font>, or their <font color="blue"><font color="blue">interpretation</font>s</font>, or the  <font color="blue">enactment</font> of new laws or the issuance of new <font color="blue">regulations</font> could <font color="blue">adversely affect</font>  the Companyapstas business by, among other things:          o     imposing <font color="blue">additional</font> license, registration, or <font color="blue">capital reserve</font>              <font color="blue">requirements</font>;          o     increasing its <font color="blue">administrative</font> and other costs;          o     forcing it to undergo a <font color="blue">corporate restructuring</font>;          o     increasing <font color="blue">mandated benefits</font> without corresponding premium              increases;          o     limiting its ability to engage in inter-company <font color="blue"><font color="blue">transaction</font>s</font> with              our <font color="blue">affiliates</font> and <font color="blue">subsidiaries</font>;          o     forcing it to <font color="blue">restructure</font> our <font color="blue"><font color="blue">relationships with</font> providers</font>; or          o     requiring it to implement <font color="blue">additional</font> or <font color="blue">different programs</font> and              systems</td>
    </tr>
    <tr>
      <td>- 26 -  <PAGE>    It is possible that <font color="blue">future legislation</font> and regulation and the <font color="blue">interpretation</font> of  existing and <font color="blue">future laws</font> and <font color="blue">regulations</font> could have a material adverse effect on  the Companyapstas ability to operate under the Medicare program and to continue to  serve <font color="blue"><font color="blue">Participating Members</font> </font>and attract new <font color="blue">Participating Members</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Health Care Industry </font>is Highly Regulated the Companyapstas Failure to Comply  with Laws or Regulations, or a De<font color="blue">termination</font> that in the <font color="blue">Past It Had Failed </font>to  Comply with Laws or Regulations, Could Have an <font color="blue">Adverse Effect </font>on the Companyapstas  Business, Financial Condition and Results of Operations</td>
    </tr>
    <tr>
      <td>The <font color="blue">health care services</font> that <font color="blue">the Company </font>and its <font color="blue">affiliated</font> <font color="blue">professionals</font>  provide are subject to extensive federal, state and local laws and <font color="blue">regulations</font>  governing various matters such as the licensing and <font color="blue">certification</font> of its  <font color="blue">facilities</font> and personnel, the conduct of its <font color="blue">operations</font>, billing and coding  policies and practices, policies and practices with regard to patient privacy  and <font color="blue">confidentiality</font>, and <font color="blue">prohibitions</font> on payments for the referral of business  and self-referrals</td>
    </tr>
    <tr>
      <td>These laws are <font color="blue">generally aimed at protecting patients</font> and  not <font color="blue"><font color="blue">shareholder</font>s</font> of <font color="blue">Metropolitan </font>and the <font color="blue">agencies charged with</font> the  <font color="blue">administration</font> of these laws have <font color="blue">broad authority</font> to <font color="blue">enforce them</font></td>
    </tr>
    <tr>
      <td>BUSINESS - Government Regulation &amp;quote  for a discussion of the <font color="blue">various federal</font>  <font color="blue">government</font> and the State laws and <font color="blue">regulations</font> to which we are subject</td>
    </tr>
    <tr>
      <td>The federal and state <font color="blue">agencies administering</font> the laws and <font color="blue">regulations</font> applicable  to <font color="blue">Metropolitan </font>have <font color="blue">broad discretion</font> to <font color="blue">enforce them</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is subject,  on an <font color="blue">ongoing basis</font>, to various <font color="blue">government</font>al reviews, audits, and <font color="blue"><font color="blue">investigation</font>s</font>  to verify its <font color="blue">compliance with</font> its contracts, licenses, and <font color="blue">applicable laws</font> and  <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>These reviews, audits and <font color="blue"><font color="blue">investigation</font>s</font> can be time consuming and  costly</td>
    </tr>
    <tr>
      <td>An adverse review, audit, or <font color="blue">investigation</font> could result in any of the  following:          o     loss of the PSNapstas or MHPapstas right to directly or <font color="blue">indirectly</font>              <font color="blue">participate</font> in the Medicare program;          o     loss of one or more of the PSNapstas and/or MHPapstas licenses to act as a              service provider, HMO or third party <font color="blue">administrator</font> or to otherwise              provide a service;          o     forfeiture or <font color="blue">recoupment</font> of amounts the PSN and/or MHP has been paid              pursuant to its contracts;          o     imposition of <font color="blue">significant</font> civil or <font color="blue">criminal penalties</font>, fines, or              other <font color="blue">sanctions on</font> <font color="blue">the Company </font>and its key employees;          o     damage to the Companyapstas reputation in existing and potential              markets;          o     <font color="blue">increased restrictions on marketing</font> of the PSNapstas or MHPapstas products              and services; and          o     <font color="blue">inability</font> to obtain approval for <font color="blue">future products</font> and services,              <font color="blue">geographic expansions</font>, or <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>The US <font color="blue">Department of Health and Human Services </font>Office of the Inspector  General, Office of Audit Services, or OIG, is conducting a <font color="blue">national review</font> of  <font color="blue">Medicare Advantage </font>plans to determine whether they used <font color="blue">payment increase</font>s  <font color="blue">consistent with</font> the <font color="blue">requirements</font> of the MMA Under the MMA, when a <font color="blue">Medicare  </font>Advantage plan receives a <font color="blue">payment increase</font>, it <font color="blue">must reduce beneficiary premiums</font>  or cost sharing, enhance benefits, put <font color="blue">additional</font> payment amounts in a benefit  <font color="blue">stabilization fund</font>, or use the <font color="blue">additional</font> payment amounts to stabilize or  <font color="blue">enhance access</font></td>
    </tr>
    <tr>
      <td>There can be <font color="blue">no assurances</font> that the findings of an audit or  <font color="blue">investigation</font> of the Companyapstas business would not have an adverse effect on it  or require substantial <font color="blue">modifications</font> to its <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, private  citizens, acting <font color="blue">as whistleblowers</font>, are entitled to <font color="blue">bring <font color="blue">enforcement</font> actions</font>  under a <font color="blue">special provision</font> of the federal <font color="blue">False Claims Act</font></td>
    </tr>
    <tr>
      <td>Direct <font color="blue"><font color="blue">medical expense</font>s</font> incurred by <font color="blue">the Company </font>include <font color="blue">costs paid by</font> Humana on  its behalf</td>
    </tr>
    <tr>
      <td>These <font color="blue">costs also</font> include estimates of claims <font color="blue">incurred but</font> not  reported ( &amp;quote IBNR &amp;quote )</td>
    </tr>
    <tr>
      <td>The IBNR estimates are made by Humana <font color="blue">utilizing actuarial</font>  methods and are <font color="blue">continually evaluated</font> and <font color="blue">adjusted by</font> the Companyapstas <font color="blue">management</font>,  <font color="blue">based upon</font> its specific claims experience</td>
    </tr>
    <tr>
      <td>Adjustments, if <font color="blue">necessary</font>, are made  to direct <font color="blue"><font color="blue">medical expense</font>s</font> when the <font color="blue">criteria used</font> to determine IBNR change and  when actual claim costs are ultimately determined</td>
    </tr>
    <tr>
      <td>With regards to MHP, the cost  of medical benefits includes an IBNR estimate <font color="blue">based on</font> <font color="blue">management</font>apstas best  estimate of <font color="blue">medical benefits payable</font>, in <font color="blue">conjunction with</font> an in<font color="blue">dependent</font>  <font color="blue">actuarial firm</font></td>
    </tr>
    <tr>
      <td>Due to the inherent uncertainties <font color="blue">associated with</font> the factors  used in these estimations, <font color="blue">materially</font> different amounts could be reported in the  Companyapstas <font color="blue">financial statements</font> for a <font color="blue">particular period under different possible</font>  <font color="blue">conditions</font> or using different, but still reasonable, assumptions</td>
    </tr>
    <tr>
      <td>Although its  past estimates of IBNR have <font color="blue">typically been adequate</font>, they may be inadequate in  the future, which <font color="blue">would <font color="blue">adversely affect</font></font> the Companyapstas results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Further, the <font color="blue">inability</font> to estimate IBNR <font color="blue">accurately may also affect</font> its ability  to take timely corrective actions, further exacerbating the extent of any  adverse effect on its results</td>
    </tr>
    <tr>
      <td>MHP is subject to state <font color="blue">regulations</font> that, among other things, require the  maintenance of <font color="blue">minimum levels</font> of <font color="blue">statutory capital</font>, or net worth</td>
    </tr>
    <tr>
      <td>The State of  Florida may raise the <font color="blue">statutory capital</font> level from time to time</td>
    </tr>
    <tr>
      <td>Other states  have adopted risk-based capital <font color="blue">requirements</font> <font color="blue">based on</font> guidelines adopted by the  National Association of Insurance Commissioners, which tend to be, although are  not necessarily, <font color="blue">higher than</font> existing <font color="blue">statutory capital</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regardless  </font>of whether Florida adopts risk-based capital <font color="blue">requirements</font>, the Florida state  department of insurance can require MHP to maintain <font color="blue">minimum levels</font> of statutory  capital in excess of amounts required under the applicable state laws if it  determines that maintaining <font color="blue">additional</font> <font color="blue">statutory capital</font> is in the best  interests of MHPapstas <font color="blue">Participating Members</font></td>
    </tr>
    <tr>
      <td>Any increases in these <font color="blue">requirements</font>  could <font color="blue">materially</font> increase our reserve <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>In addition, as it continues  to expand plan offerings in Florida or pursue new business <font color="blue">opportunities</font>, MHP  may be required to maintain <font color="blue">additional</font> statutory <font color="blue">capital reserve</font>s</td>
    </tr>
    <tr>
      <td>In either  case, available funds could be <font color="blue">materially</font> reduced, <font color="blue">which could</font> harm the  Companyapstas ability to implement its business strategy</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>Is Required to Comply With Laws Governing the Transmission, Security  and Privacy of Health Information That Require Significant Compliance Costs, and  Any Failure to Comply With These Laws Could Result in Material Criminal and  <font color="blue">Civil Penalties</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulations </font>under the Health Insurance Portability and Accountability Act of  1996, or HIPAA, require <font color="blue">the Company </font>to <font color="blue">comply with</font> standards regarding the  exchange of health information within its company and with third parties,  including <font color="blue">healthcare providers</font>, business <font color="blue">associates</font> and members</td>
    </tr>
    <tr>
      <td>These  <font color="blue">regulations</font> include standards for <font color="blue">common healthcare <font color="blue"><font color="blue">transaction</font>s</font></font>, including  claims information, plan <font color="blue">eligibility</font>, and payment information; unique  <font color="blue">identifiers</font> for providers and employers; security; privacy; and <font color="blue">enforcement</font></td>
    </tr>
    <tr>
      <td>HIPAA <font color="blue">also provides</font> that to the extent that state laws impose stricter privacy  standards than HIPAA privacy <font color="blue">regulations</font>, a state seeks and receives an  <font color="blue">exception from</font> the <font color="blue">Department of Health and Human Services </font>regarding certain  state laws, or state laws concern certain specified areas, such state standards  and laws are not preempted</td>
    </tr>
    <tr>
      <td>- 28 -  <PAGE>    <font color="blue">The Company </font><font color="blue">will conduct</font> its <font color="blue">operations</font> in an attempt to <font color="blue">comply with</font> all  applicable HIPAA <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Given the <font color="blue">complexity</font> <font color="blue">of <font color="blue">the HIPAA </font></font><font color="blue">regulations</font>,  the <font color="blue">possibility</font> that the <font color="blue">regulations</font> may change, and the fact that the  <font color="blue">regulations</font> are subject to changing and, at times, conflicting <font color="blue">interpretation</font>,  its <font color="blue">ongoing ability</font> to <font color="blue">comply with</font> <font color="blue">the HIPAA </font><font color="blue">requirements</font> is uncertain</td>
    </tr>
    <tr>
      <td>Furthermore, a stateapstas ability to promulgate stricter laws, and un<font color="blue">certainty</font>  regarding many aspects of such state <font color="blue">requirements</font>, make compliance more  <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>To the extent that <font color="blue">the Company </font><font color="blue">submits electronic healthcare</font> claims  and <font color="blue">payment <font color="blue"><font color="blue">transaction</font>s</font></font> that do not <font color="blue">comply with</font> the <font color="blue">electronic data</font>  <font color="blue">transmission standards established under</font> HIPAA, <font color="blue">payments may</font> be delayed or  denied</td>
    </tr>
    <tr>
      <td>Additionally, the costs of complying with any changes <font color="blue">to <font color="blue">the HIPAA </font> </font><font color="blue">regulations</font> may have a negative impact on <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Sanctions </font>for failing to  <font color="blue">comply with</font> <font color="blue">the HIPAA </font>health information provisions include <font color="blue">criminal penalties</font>  and <font color="blue">civil sanctions</font>, including <font color="blue">significant</font> monetary penalties</td>
    </tr>
    <tr>
      <td>In addition,  failure to <font color="blue">comply with</font> state health information laws that may be more  <font color="blue">restrictive than</font> the <font color="blue">regulations</font> issued under HIPAA could result in <font color="blue">additional</font>  penalties</td>
    </tr>
    <tr>
      <td><font color="blue">Recent Challenges Faced </font>by CMS Related to Implementation of Part D May  Temporarily Disrupt or Adversely the PSNapstas and MHPapstas Relationships with their  <font color="blue">Respective Members</font></td>
    </tr>
    <tr>
      <td><font color="blue">Partially </font>in <font color="blue">anticipation</font> of the <font color="blue">implementation</font> of Part D, CMS <font color="blue">transitioned</font> to  new information and reporting systems, which have <font color="blue">recently generated confusing</font>  and, <font color="blue">the Company </font>believes in some cases, erroneous <font color="blue">membership</font> and payment  reports <font color="blue">concerning</font> Medicare <font color="blue">eligibility</font> and <font color="blue">enrollment</font>, most of which it  believes reflects inadvertently disenrolled dual-eligible and other  <font color="blue">beneficiaries</font> who were <font color="blue">already members</font> of the Companyapstas PSN or HMO In addition,  <font color="blue">recent media</font> reports are prevalent <font color="blue">concerning</font> the confusion caused <font color="blue">by failures</font>  in systems and reporting for Part D, <font color="blue">particularly</font> as these <font color="blue">failures adversely</font>  affect the access of dual-eligibles and low-income <font color="blue">beneficiaries</font> to their  <font color="blue">prescription drug</font>s</td>
    </tr>
    <tr>
      <td>These <font color="blue">development</font>s have caused the Companyapstas business to  experience short-term disruptions in its <font color="blue">operations</font> and challenged its  information and <font color="blue">communications systems</font></td>
    </tr>
    <tr>
      <td>Although <font color="blue">the Company </font>believes the  current <font color="blue">conditions</font> are temporary, there can be no assurance that the current  confusion, systems failures, and <font color="blue">mistaken payment</font> reports will not <font color="blue">temporarily</font>  disrupt or <font color="blue">adversely affect</font> the PSNapstas or MHPapstas <font color="blue">relationships with</font> their  respective members, <font color="blue">which could</font> result in a reduction of <font color="blue">membership</font> and  <font color="blue">adversely affect</font> its results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">There Can </font>be <font color="blue">No Assurance </font>that <font color="blue">The Company </font>Will be Successful in Its Operation  of MHP    Although <font color="blue">the Company </font>has operated as a risk provider since 1997, it has only  operated MHP since July 1, 2005</td>
    </tr>
    <tr>
      <td>To <font color="blue">successfully</font> operate MHP, <font color="blue">the Company </font> believes it will have to continue its <font color="blue">development</font> of the <font color="blue">following capabilities</font>,  among others: sales and marketing, customer service and <font color="blue">regulatory</font> compliance</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>anticipates that the continued <font color="blue">development</font> efforts and reserve  <font color="blue">requirements</font> for MHP can be <font color="blue">funded by</font> the Companyapstas <font color="blue">current resources</font> and  projected <font color="blue">cash flows</font> from <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>expects to <font color="blue">spend approximately</font>  dlra3dtta0 million to dlra5dtta0 million of its existing or <font color="blue">future cash resources</font> in 2006 to  continue <font color="blue">development</font> and expansion of MHP No assurances can be given that the  Company will be successful in operating this segment of its business despite its  <font color="blue">allocation</font> of a substantial amount of resources for this purpose</td>
    </tr>
    <tr>
      <td>If MHP does  not develop as anticipated or planned, <font color="blue">the Company </font>may have to devote <font color="blue">additional</font>  managerial and/or capital resources to MHP, <font color="blue">which could</font> limit the Companyapstas  ability to manage and/or grow its PSN                                           - 29 -  <PAGE>    <font color="blue">The Company </font>May Be Unsuccessful in Implementing Its Growth Strategy If It Is  Unable to Expand into <font color="blue">New Service Areas in a Timely Manner in Accordance </font>with  <font color="blue">Its Strategic Plans</font></td>
    </tr>
    <tr>
      <td>The Companyapstas strategy is to continue to <font color="blue">focus on growth within certain</font>  <font color="blue">geographic regions</font> of Florida</td>
    </tr>
    <tr>
      <td><font color="blue">Continued </font><font color="blue">growth may impair</font> its ability to manage  its existing <font color="blue">operations</font> and provide its <font color="blue">services efficiently</font> and to manage its  employees <font color="blue">adequately</font></td>
    </tr>
    <tr>
      <td>Future results of <font color="blue">operations</font> could be <font color="blue">materially</font> adversely  affected if it is unable to manage its growth efforts <font color="blue">effectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is seeking to continue to increase <font color="blue">PSN and MHP </font><font color="blue">membership</font> and to  expand to new <font color="blue">service areas</font> within its <font color="blue">existing markets</font> and in other markets</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is likely to incur <font color="blue">additional</font> costs if the <font color="blue">PSN or MHP </font><font color="blue">enters new</font>  <font color="blue">service areas</font> in Florida where they do not <font color="blue">respectively currently</font> operate</td>
    </tr>
    <tr>
      <td>The  Companyapstas rate of <font color="blue">expansion into new geographic areas may also</font> be limited by:          o     the time and costs <font color="blue">associated with</font> obtaining an HMO license to              operate in the new area or expanding MHPapstas licensed service area, as              the case may be;          o     the PSN and/or MHPapstas <font color="blue">inability</font> to develop a network of physicians,              hospitals, and other <font color="blue">healthcare providers</font> that meets their              respecitve <font color="blue">requirements</font> and those of the <font color="blue">applicable regulators</font>;          o     competition, <font color="blue">which could</font> increase the costs of <font color="blue">recruiting members</font>,              reduce the pool of <font color="blue">available members</font>, or increase the cost of              attracting and maintaining providers;          o     the cost of providing <font color="blue">healthcare services</font> in those areas;          o     <font color="blue">demographics</font> and <font color="blue">population density</font>; and          o     the new annual <font color="blue">enrollment</font> period and lock-in provisions of the MMA    <font color="blue">The Company </font>has Anti-Takeover Provisions Which May Make it Difficult to Acquire  It or Replace or Remove Current Management</td>
    </tr>
    <tr>
      <td>Provisions in the Companyapstas Articles of Incorporation and Bylaws may delay or  prevent an <font color="blue">acquisition</font> of it or a change in its <font color="blue">management</font> or similar change in  <font color="blue">control <font color="blue">transaction</font></font>, including <font color="blue"><font color="blue">transaction</font>s</font> in which its <font color="blue"><font color="blue">shareholder</font>s</font> might  otherwise receive a premium for their <font color="blue">shares over then current prices</font> or that  <font color="blue"><font color="blue">shareholder</font>s</font> may deem to be in their <font color="blue">best interests</font></td>
    </tr>
    <tr>
      <td>In addition, these  <font color="blue">provisions may frustrate</font> or prevent any <font color="blue">attempts by</font> the Companyapstas <font color="blue"><font color="blue">shareholder</font>s</font>  to replace or remove its current <font color="blue">management</font> by making it more <font color="blue">difficult</font> for  <font color="blue"><font color="blue">shareholder</font>s</font> to <font color="blue">replace members</font> of its <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td>Because its Board of  <font color="blue">Directors </font>is responsible for appointing the members of its <font color="blue">management</font> team,  these <font color="blue">provisions could</font> in turn affect any <font color="blue">attempt by</font> its <font color="blue"><font color="blue">shareholder</font>s</font> to replace  <font color="blue">current members</font> of its <font color="blue">management</font> team</td>
    </tr>
    <tr>
      <td>These provisions provide, among other  things, that:             o    any <font color="blue">shareholder</font> wishing to <font color="blue">properly bring</font> a matter before a                meeting of <font color="blue"><font color="blue">shareholder</font>s</font> must <font color="blue">comply with</font> specified procedural and                advance notice <font color="blue">requirements</font>;                                           - 30 -  <PAGE>          o     <font color="blue">special meetings</font> of the Companyapstas <font color="blue"><font color="blue">shareholder</font>s</font> may be <font color="blue">called only by</font>              the Chairman of the <font color="blue">Board of Directors</font>, its <font color="blue">President </font>or by the              <font color="blue">Board of Directors</font> pursuant to a <font color="blue">resolution adopted by</font> a majority of              the <font color="blue">directors</font>;          o     the authorized number of <font color="blue">directors</font> may be changed <font color="blue">only by resolution</font>              of the <font color="blue">Board of Directors</font>; and          o     the <font color="blue">Board of Directors</font> has the ability to issue up to 10cmam000cmam000              shares of preferred stock, with such rights and <font color="blue">preferences as may</font>              be determined from time to time by the <font color="blue">Board of Directors</font>, without              <font color="blue">shareholder</font> approval</td>
    </tr>
    <tr>
      <td>The Companyapstas Quarterly Results Will Likely Fluctuate, Which Could Cause the  <font color="blue">Value of Its <font color="blue">Common Stock</font> to Decline</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is subject to <font color="blue">quarterly variations</font> in its <font color="blue">Total Medical Expenses </font>due  to sometimes pronounced <font color="blue">fluctuations</font> in patient <font color="blue">utilization</font></td>
    </tr>
    <tr>
      <td>It has <font color="blue">significant</font>  fixed operating costs and, as a result, is highly <font color="blue">dependent</font> on patient  <font color="blue">utilization</font> to sustain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Its results of <font color="blue">operations</font> for any quarter  are not <font color="blue">necessarily indicative</font> of results of <font color="blue">operations</font> for any <font color="blue">future period</font> or  full year</td>
    </tr>
    <tr>
      <td><font color="blue">Metropolitan </font>experiences a <font color="blue">greater use</font> of <font color="blue">medical services</font> in the  <font color="blue">winter months</font></td>
    </tr>
    <tr>
      <td>As a result, its results of <font color="blue">operations</font> may fluctuate  <font color="blue">significant</font>ly from period to period, <font color="blue">which could</font> cause the value of its Common  Stock to decline</td>
    </tr>
    <tr>
      <td>The Market Price of the Companyapstas <font color="blue">Common Stock</font> Could Fall as a Result of Sales  of Shares of <font color="blue">Common Stock</font> in the Market or the Price Could Remain Lower because  of the <font color="blue">Perception </font>that <font color="blue">Such Sales May Occur</font></td>
    </tr>
    <tr>
      <td><font color="blue">Metropolitan </font><font color="blue">cannot predict</font> the effect, if any, that <font color="blue">future sales</font> or the  <font color="blue">possibility</font> of <font color="blue">future sales</font> may have on the <font color="blue">market price</font> of its <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>As  of <font color="blue">December </font>31, 2005, there were 49cmam851cmam526 shares of its <font color="blue">Common Stock</font>  outstanding, all of which are <font color="blue">freely tradable without restriction with</font> the  exception of approximately 12cmam100cmam000 shares, owned by certain of its officers,  <font color="blue">directors</font> and <font color="blue">affiliates</font> which may be <font color="blue">sold publicly at</font> any time subject to the  volume and other <font color="blue">restrictions promulgated pursuant</font> to Rule 144 of the <font color="blue">Securities </font> Act</td>
    </tr>
    <tr>
      <td>In addition, as of <font color="blue">December </font>31, 2005, approximately 6cmam400cmam000 shares of the  Companyapstas <font color="blue">Common Stock</font> were reserved for <font color="blue">issuance upon</font> the exercise of options  which were <font color="blue">previously granted</font></td>
    </tr>
    <tr>
      <td>Sales of substantial amounts of Metropolitanapstas <font color="blue">Common Stock</font> or the <font color="blue">perception</font>  that <font color="blue">such sales could</font> occur could <font color="blue">adversely affect</font> prevailing <font color="blue">market price</font>s  <font color="blue">which could</font> impair its ability to raise funds through <font color="blue">future sales</font> of its Common  Stock</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> and <font color="blue">trading volume</font> of Metropolitanapstas <font color="blue">Common Stock</font> could  fluctuate <font color="blue">significant</font>ly and <font color="blue">unexpectedly as</font> a result of a number of factors,  including <font color="blue">factors beyond</font> the Companyapstas control and unrelated to its business</td>
    </tr>
    <tr>
      <td>Some of the factors related to Metropolitanapstas business include: <font color="blue">termination</font> of  the <font color="blue">Humana Agreements</font>, <font color="blue">announcements</font> relating to the Companyapstas business or that  of its <font color="blue"><font color="blue">competitor</font>s</font>, adverse publicity <font color="blue">concerning</font> <font color="blue"><font color="blue">organization</font>s</font> such as  Metropolitan, changes in state or <font color="blue">federal legislation</font> and programs, general  <font color="blue">conditions</font> affecting the industry, performance of <font color="blue">companies comparable</font> to the  Company, and changes in the <font color="blue">expectations</font> of <font color="blue">analysts with</font> the respect to the  Companyapstas <font color="blue">future financial performance</font></td>
    </tr>
    <tr>
      <td>Additionally, Metropolitanapstas Common  Stock may be affected by general economic <font color="blue">conditions</font> or <font color="blue">specific occurrences</font>  such as epidemics (such as influenza), natural disasters (including hurricanes),  acts of war or terrorism</td>
    </tr>
    <tr>
      <td>Because of the limited <font color="blue">trading market</font> for the  Companyapstas <font color="blue">Common Stock</font>, and because of the <font color="blue">possible <font color="blue">price volatility</font></font>, the  Companyapstas <font color="blue"><font color="blue">shareholder</font>s</font> may not be able to sell their shares of <font color="blue">Common Stock</font> when  they desire to do so</td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> to <font color="blue">sell shares</font> in a <font color="blue">rapidly declining market</font>  may <font color="blue">substantially</font> increase the Companyapstas <font color="blue"><font color="blue">shareholder</font>s</font> &amp;apos  risk of loss because of  <font color="blue">such illiquidity</font> and because the price for the Companyapstas <font color="blue">Common Stock</font> may suffer  <font color="blue">greater declines</font> because of its <font color="blue">price volatility</font></td>
    </tr>
    <tr>
      <td>- 31 -  <PAGE>    Delisting of Its <font color="blue">Common Stock</font> from AMEX Would Adversely Affect <font color="blue">the Company </font>and  <font color="blue">Its Shareholders</font></td>
    </tr>
    <tr>
      <td>Metropolitanapstas <font color="blue">Common Stock</font> is listed on the AMEX To maintain listing of  securities, the AMEX requires <font color="blue">satisfaction</font> of <font color="blue">certain maintenance criteria</font> that  <font color="blue">the Company </font>is not sure that it <font color="blue">will continue</font> to be able to satisfy</td>
    </tr>
    <tr>
      <td>If it is  unable to <font color="blue">satisfy such maintenance criteria</font> in the future and it fails to  comply, its <font color="blue">Common Stock</font> may be <font color="blue">delisted from trading on</font> AMEX If its Common  Stock is <font color="blue">delisted from trading on</font> AMEX, <font color="blue">then trading</font>, if any, <font color="blue">might thereafter</font>  be conducted in the over-the-counter market in the so-called  &amp;quote pink sheets &amp;quote  or on  the  &amp;quote <font color="blue">Electronic Bulletin Board </font>&amp;quote  of the National Association of <font color="blue">Securities </font> Dealers, Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">consequently</font> an <font color="blue">investor could find</font> it more <font color="blue">difficult</font> to  dispose of, or to obtain accurate <font color="blue">quotations as</font> to the price of, the Companyapstas  <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue">Common Stock</font> May Not be Excepted from  &amp;quote <font color="blue">Penny Stock </font>&amp;quote  Rules, Which  May Adversely Affect the Market Liquidity of Our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">Securities </font>Enforcement and <font color="blue">Penny Stock </font>Reform Act of 1990 requires  <font color="blue">additional</font> <font color="blue">disclosure</font> relating to the market for <font color="blue"><font color="blue">penny stock</font>s</font> in <font color="blue">connection with</font>  trades in any <font color="blue">stock defined as</font> a  &amp;quote <font color="blue">penny stock</font> &amp;quote</td>
    </tr>
    <tr>
      <td>The <font color="blue">Securities </font>Exchange  Commissionapstas (the  &amp;quote <font color="blue">Commission </font>&amp;quote  or the  &amp;quote SEC &amp;quote ) <font color="blue">regulations</font> generally define a  <font color="blue">penny stock</font> to be an <font color="blue">equity security</font> that has a <font color="blue">market price</font> of less than dlra5dtta00  per share, subject to <font color="blue">certain exceptions</font></td>
    </tr>
    <tr>
      <td>For example, such exceptions include  any <font color="blue">equity security</font> listed on a <font color="blue">national securities exchange such as</font> the AMEX  Currently, Metropolitanapstas <font color="blue">Common Stock</font> meets this exception</td>
    </tr>
    <tr>
      <td>Unless an exception  is available, the <font color="blue">regulations</font> require the delivery, prior to any <font color="blue">transaction</font>  involving a <font color="blue">penny stock</font>, of a <font color="blue">disclosure</font> schedule explaining the <font color="blue">penny stock</font>  market and the <font color="blue">risks associated therewith</font></td>
    </tr>
    <tr>
      <td>In addition, if our <font color="blue">Common Stock</font>  becomes delisted from the AMEX and we do not meet another exception to the penny  stock <font color="blue">regulations</font>, trading in its <font color="blue">Common Stock</font> would be <font color="blue">covered by</font> the  Commissionapstas Rule 15g-9 under the <font color="blue">Exchange Act </font>for non-national securities  exchange listed securities</td>
    </tr>
    <tr>
      <td>Under this rule, broker/dealers who <font color="blue">recommend such</font>  securities to persons other <font color="blue">than established customers</font> and <font color="blue">accredited investors</font>  must make a special written suitability de<font color="blue">termination</font> for the purchaser and  receive the purchaserapstas written agreement to a <font color="blue">transaction</font> prior to sale</td>
    </tr>
    <tr>
      <td><font color="blue">Securities </font>also are <font color="blue">exempt from</font> this rule if the <font color="blue">market price</font> is at least dlra5dtta00  per share</td>
    </tr>
    <tr>
      <td>If the Companyapstas <font color="blue">Common Stock</font> becomes subject to the <font color="blue">regulations</font>  applicable to <font color="blue"><font color="blue">penny stock</font>s</font>, the <font color="blue">market liquidity</font> for its <font color="blue">Common Stock</font> could be  <font color="blue">adversely affect</font>ed</td>
    </tr>
    <tr>
      <td>In such event, the <font color="blue">regulations</font> on <font color="blue"><font color="blue">penny stock</font>s</font> could limit  the ability of broker/dealers to sell Metropolitanapstas <font color="blue">Common Stock</font> and thus the  ability of purchasers of its <font color="blue">Common Stock</font> to sell their shares in the secondary  market</td>
    </tr>
  </tbody>
</table>